Tumor angiogenesis: Pericytes and maturation are not to be ignored

Journal of Oncology

Volumn , Issue , 2012, Pages

  Fakhrejahani, Elham ^a   Toi, Masakazu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; CABOZANTINIB; CAPECITABINE; CD34 ANTIGEN; FORETINIB; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HYPERTENSION; NONHUMAN; PANCREAS ISLET CELL TUMOR; PERICYTE; PROGNOSIS; QUANTITATIVE ANALYSIS; REVIEW; TUMOR VASCULARIZATION; TUMOR VESSEL MATURITY;

EID: 84855280109     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/261750     Document Type: Review

References (93)

1. Carmeliet P., Angiogenesis in life, disease and medicine Nature 2005 438 7070 932 936 (Pubitemid 43093958)
2. Carmeliet P., Jain R. K., Angiogenesis in cancer and other diseases Nature 2000 407 6801 249 257
3. Folkman J., Tumor angiogenesis: therapeutic implications The New England Journal of Medicine 1971 285 21 1182 1186
4. Engerman R. L., Pfaffenbach D., Davis M. D., Cell turnover of capillaries Laboratory Investigation 1967 17 6 738 743
5. Hanahan D., Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996 86 3 353 364 (Pubitemid 26272076)
6. Asahara T., Masuda H., Takahashi T., Kalka C., Pastore C., Silver M., Kearne M., Magner M., Isner J. M., Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization Circulation Research 1999 85 3 221 228 (Pubitemid 29377293)
7. Marmé D., Fusenig N., Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy 2007 Berlin, Germany Spinger
8. Zhang Z., Neiva K. G., Lingen M. W., Ellis L. M., Nr J. E., VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2 Cell Death and Differentiation 2010 17 3 499 512
9. Raza A., Franklin M. J., Dudek A. Z., Pericytes and vessel maturation during tumor angiogenesis and metastasis American Journal of Hematology 2010 85 8 593 598
10. Kalluri R., Basement membranes: structure, assembly and role in tumour angiogenesis Nature Reviews Cancer 2003 3 6 422 433 (Pubitemid 37328846)
11. Fox S. B., Gatter K. C., Bicknell R., Going J. J., Stanton P., Cooke T. G., Harris A. L., Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer Cancer Research 1993 53 18 4161 4163 (Pubitemid 24146759)
12. Toffoli S., Roegiers A., Feron O., Van Steenbrugge M., Ninane N., Raes M., Michiels C., Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1 Angiogenesis 2009 12 1 47 67
13. Gillies R. J., Schornack P. A., Secomb T. W., Raghunand N., Causes and effects of heterogeneous perfusion in tumors Neoplasia 1999 1 3 197 207
14. Fox S. B., Generali D. G., Harris A. L., Breast tumour angiogenesis Breast Cancer Research 2007 9 6 216
15. Engels K., Fox S. B., Whitehouse R. M., Gatter K. C., Harris A. L., Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast Journal of Pathology 1997 181 2 207 212 (Pubitemid 27087287)
16. Fox S. B., Leek R. D., Bliss J., Mansi J. L., Gusterson B., Gatter K. C., Harris A. L., Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients Journal of the National Cancer Institute 1997 89 14 1044 1049 (Pubitemid 27327869)
17. Barnes D. M., Millis R. R., Gillett C. E., Ryder K., Skilton D., Fentiman I. S., Rubens R. D., The interaction of oestrogen receptor status and pathological features with adjuvant treatment in relation to survival in patients with operable breast cancer: a retrospective study of 2660 patients Endocrine-Related Cancer 2004 11 1 85 96 (Pubitemid 38419725)
18. Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2 The New England Journal of Medicine 2001 344 11 783 792 (Pubitemid 32222155)
19. Callahan R., Hurvitz S., Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease Current Opinion in Obstetrics and Gynecology 2011 23 1 37 43
20. Foulkes W. D., Smith I. E., Reis-Filho J. S., Triple-negative breast cancer The New England Journal of Medicine 2010 363 20 1938 1948
21. Perou C. M., Srile T., Eisen M. B., Van De Rijn M., Jeffrey S. S., Ress C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A., Fluge., Pergammenschlkov A., Williams C., Zhu S. X., Lnning P. E., Brresen-Dale A. L., Brown P. O., Botstein D., Molecular portraits of human breast tumours Nature 2000 406 6797 747 752
22. Prat A., Parker J. S., Karginova O., Fan C., Livasy C., Herschkowitz J. I., He X., Perou C. M., Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer Breast Cancer Research 2010 12 5, article no. R68
23. Carey L. A., Perou C. M., Livasy C. A., Dressler L. G., Cowan D., Conway K., Karaca G., Troester M. A., Chiu K. T., Edmiston S., Deming S. L., Geradts J., Cheang M. C. U., Nielsen T. O., Moorman P. G., Earp H. S., Millikan R. C., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study Journal of the American Medical Association 2006 295 21 2492 2502 (Pubitemid 43854964)
24. Liu Y., Tamimi R. M., Collins L. C., The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study Breast Cancer Research and Treatment 2011 129 1 175 184
25. Sarmiento R., D'Andrea M. R., Cacciamani F., Salerno F., Gasparini G., Antiangiogenic therapies in breast cancer Current Opinion in Investigational Drugs 2009 10 12 1334 1345
26. Valachis A., Polyzos N. P., Patsopoulos N. A., Georgoulias V., Mavroudis D., Mauri D., Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials Breast Cancer Research and Treatment 2010 122 1 1 7
27. Rydén L., Jirstrom K., Haglund M., Stal O., Fern M., Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up Breast Cancer Research and Treatment 2010 120 2 491 498
28. Camp J. T., Elloumi F., Roman-Perez E., Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers Molecular Cancer Research 2011 9 1 3 13
29. Mohammed R. A., Ellis I. O., Mahmmod A. M., Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance Modern Pathology 2011 24 6 774 785
30. Asahara T., Murohara T., Sullivan A., Silver M., Van Der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J. M., Isolation of putative progenitor endothelial cells for angiogenesis Science 1997 275 5302 964 967 (Pubitemid 27087709)
31. Kennecke H., Yerushalmi R., Woods R., Cheang M. C., Voduc D., Speers C. H., Nielsen T. O., Gelmon K., Metastatic behavior of breast cancer subtypes Journal of Clinical Oncology 2010 28 20 3271 3277
32. Harfouche R., Echavarria R., Rabbani S. A., Arakelian A., Hussein M. A., Hussain S. N. A., Estradiol-dependent regulation of angiopoietin expression in breast cancer cells Journal of Steroid Biochemistry and Molecular Biology 2011 123 1-2 17 24
33. Slade M. J., Payne R., Riethdorf S., Ward B., Zaidi S. A. A., Stebbing J., Palmieri C., Sinnett H. D., Kulinskaya E., Pitfield T., McCormack R. T., Pantel K., Coombes R. C., Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment British Journal of Cancer 2009 100 1 160 166
34. Liang Y., Brekken R. A., Hyder S. M., Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones Endocrine-Related Cancer 2006 13 3 905 919 (Pubitemid 44763266)
35. Kallergi G., Markomanolaki H., Giannoukaraki V., Papadaki M. A., Strati A., Lianidou E. S., Georgoulias V., Mavroudis D., Agelaki S., Hypoxia-inducible factor-1 and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients Breast Cancer Research 2009 11 6, article no. R84
36. Hu Z., Fan C., Livasy C., He X., Oh D. S., Ewend M. G., Carey L. A., Subramanian S., West R., Ikpatt F., Olopade O. I., van de Rijn M., Perou C. M., A compact VEGF signature associated with distant metastases and poor outcomes BMC Medicine 2009 7, article no. 9
37. Ito Y., Oike Y., Yasunaga K., Hamada K., Miyata K., Matsumoto S. I., Sugano S., Tanihara H., Masuho Y., Suda T., Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4 Cancer Research 2003 63 20 6651 6657 (Pubitemid 37322943)
38. Fritz-Six K. L., Dunworth W. P., Li M., Caron K. M., Adrenomedullin signaling is necessary for murine lymphatic vascular development Journal of Clinical Investigation 2008 118 1 40 50
39. Narod S. A., BRCA mutations in the management of breast cancer: the state of the art Nature Reviews Clinical Oncology 2010 7 12 702 707
40. Van Der Groep P., Bouter A., Menko F. H., Van Der Wall E., Van Diest P. J., High frequency of HIF-1 overexpression in BRCA1 related breast cancer Breast Cancer Research and Treatment 2008 111 3 475 480
41. Yan M., Rayoo M., Takano E. A., Thorne H., Fox S. B., BRCA1 tumours correlate with a HIF-1 phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression British Journal of Cancer 2009 101 7 1168 1174
42. Tamaki K., Sasano H., Maruo Y., Takahashi Y., Miyashita M., Moriya T., Sato Y., Hirakawa H., Tamaki N., Watanabe M., Ishida T., Ohuchi N., Vasohibin-1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast Cancer science 2010 101 4 1051 1058
43. Gately S., Li W. W., Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy Seminars in Oncology 2004 31 7 2 11 (Pubitemid 38879409)
44. Kumagai Y., Toi M., Inoue H., Dynamism of tumour vasculature in the early phase of cancer progression: outcomes from oesophageal cancer research The Lancet Oncology 2002 3 10 604 610 (Pubitemid 35174679)
45. Perrone G., Santini D., Vincenzi B., Zagami M., La Cesa A., Bianchi A., Altomare V., Primavera A., Battista C., Vetrani A., Tonini G., Rabitti C., COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features Histopathology 2005 46 5 561 568 (Pubitemid 40632313)
46. Hu M., Peluffo G., Chen H., Gelman R., Schnitt S., Polyak K., Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast Proceedings of the National Academy of Sciences of the United States of America 2009 106 9 3372 3377
47. Jain R. K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 2005 307 5706 58 62 (Pubitemid 40093472)
48. Benjamin L. E., Hemo I., Keshet E., A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF Development 1998 125 9 1591 1598 (Pubitemid 28256727)
49. Lamagna C., Bergers G., The bone marrow constitutes a reservoir of pericyte progenitors Journal of Leukocyte Biology 2006 80 4 677 681 (Pubitemid 44835880)
50. Bergers G., Song S., The role of pericytes in blood-vessel formation and maintenance Neuro-Oncology 2005 7 4 452 464 (Pubitemid 41555617)
51. Abramsson A., Lindblom P., Betsholtz C., Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors Journal of Clinical Investigation 2003 112 8 1142 1151 (Pubitemid 38056291)
52. Huang J., Softer S. Z., Kim E. S., McCrudden K. W., Huang J., New T., Manley C. A., Middlesworth W., O'Toole K., Yamashiro D. J., Kandel J. J., Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis Molecular Cancer Research 2004 2 1 36 42 (Pubitemid 38167106)
53. Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., Kaminker J., Ferrara N., PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment Cancer Cell 2009 15 1 21 34
54. Jubb A. M., Harris A. L., Biomarkers to predict the clinical efficacy of bevacizumab in cancer The Lancet Oncology 2010 11 12 1172 1183
55. Dvorak H. F., Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy Journal of Clinical Oncology 2002 20 21 4368 4380 (Pubitemid 35266299)
56. Ranpura V., Pulipati B., Chu D., Zhu X., Wu S., Increased risk of high-grade hypertension with bevacizumab in cancer patients: a Meta-Analysis American Journal of Hypertension 2010 23 5 460 468
57. sterlund P., Soveri L. M., Isoniemi H., Poussa T., Alanko T., Bono P., Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy British Journal of Cancer 2011 104 4 599 604
58. Bono P., Elfving H., Utriainen T., sterlund P., Saarto T., Alanko T., Joensuu H., Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma Annals of Oncology 2009 20 2 393 394
59. Dahlberg S. E., Sandler A. B., Brahmer J. R., Schiller J. H., Johnson D. H., Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 Journal of Clinical Oncology 2010 28 6 949 954
60. Schneider B. P., Wang M., Radovich M., Sledge G. W., Badve S., Thor A., Flockhart D. A., Hancock B., Davidson N., Gralow J., Dickler M., Perez E. A., Cobleigh M., Shenkier T., Edgerton S., Miller K. D., Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100 Journal of Clinical Oncology 2008 26 28 4672 4678
61. Jubb A. M., Miller K. D., Rugo H. S., Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer Clinical Cancer Research 2011 17 2 372 381
62. Xu L., Duda D. G., Di Tomaso E., Ancukiewicz M., Chung D. C., Lauwers G. Y., Samuel R., Shellito P., Czito B. G., Lin P. C., Poleski M., Bentley R., Clark J. W., Willett C. G., Jain R. K., Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer Cancer Research 2009 69 20 7905 7910
63. Marcus K., Johnson M., Adam R. M., O'Reilly M. S., Donovan M., Atala A., Freeman M. R., Soker S., Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma Neuropathology 2005 25 3 178 187 (Pubitemid 41602601)
64. Geretti E., Van Meeteren L. A., Shimizu A., Dudley A. C., Claesson-Welsh L., Klagsbrun M., A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression Molecular Cancer Research 2010 8 8 1063 1073
65. Real C., Remédio L., Caiado F., Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis PLoS ONE 2011 6 4, article e18323
66. Stewart K. S., Zhou Z., Zweidler-McKay P., Kleinerman E. S., Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation Blood 2011 117 2 719 726
67. Ridgway J., Zhang G., Wu Y., Stawicki S., Liang W. C., Chanthery Y., Kowalski J., Watts R. J., Callahan C., Kasman I., Singh M., Chien M., Tan C., Hongo J. A. S., De Sauvage F., Plowman G., Yan M., Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis Nature 2006 444 7122 1083 1087 (Pubitemid 46018529)
68. Patel N. S., Dobbie M. S., Rochester M., Steers G., Poulsom R., Le Monnier K., Cranston D. W., Li J. L., Harris A. L., Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer Clinical Cancer Research 2006 12 16 4836 4844 (Pubitemid 44338568)
69. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., Matsushima K., Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer Clinical Cancer Research 2000 6 8 3282 3289 (Pubitemid 30637758)
70. Ma J., Wang Q., Fei T., Han J. D. J., Chen Y. G., MCP-1 mediates TGF- -induced angiogenesis by stimulating vascular smooth muscle cell migration Blood 2007 109 3 987 994 (Pubitemid 46220643)
71. Qian B. Z., Li J., Zhang H., CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis Nature 2011 475 7255 222 225
72. Dhar K., Dhar G., Majumder M., Haque I., Mehta S., Van Veldhuizen P. J., Banerjee S. K., Banerjee S., Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1 Molecular Cancer 2010 9, article no. 209
73. Song N., Huang Y., Shi H., Yuan S., Ding Y., Song X., Fu Y., Luo Y., Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1 /CXCR4 axis Cancer Research 2009 69 15 6057 6064
74. Hedlund E. M., Hosaka K., Zhong Z., Cao R., Cao Y., Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature Proceedings of the National Academy of Sciences of the United States of America 2009 106 41 17505 17510
75. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D., Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors Journal of Clinical Investigation 2003 111 9 1287 1295 (Pubitemid 36554699)
76. stman A., Heldin C. H., PDGF receptors as targets in tumor treatment Advances in Cancer Research 2007 97 247 274
77. Ma H., Calderon T. M., Kessel T., Ashton A. W., Berman J. W., Mechanisms of hepatocyte growth factor-mediated vascular smooth muscle cell migration Circulation Research 2003 93 11 1066 1073 (Pubitemid 37485037)
78. Kobayashi H., DeBusk L. M., Babichev Y. O., Dumont D. J., Lin P. C., Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment Blood 2006 108 4 1260 1266 (Pubitemid 44232023)
79. You W. K., Sennino B., Williamson C. W., VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer Cancer Research 2011 71 14 4758 4758
80. James K., Eisenhauer E., Christian M., Terenziani M., Vena D., Muldal A., Therasse P., Measuring response in solid tumors: unidimensional versus bidimensional measurement Journal of the National Cancer Institute 1999 91 6 523 528 (Pubitemid 29157060)
81. Laking G. R., Price P. M., Positron emission tomographic imaging of angiogenesis and vascular function British Journal of Radiology 2003 76 1 S50 S59 (Pubitemid 39530316)
82. Barrett T., Brechbiel M., Bernardo M., Choyke P. L., MRI of tumor angiogenesis Journal of Magnetic Resonance Imaging 2007 26 2 235 249 (Pubitemid 47257720)
83. O'Connor J. P. B., Carano R. A. D., Clamp A. R., Ross J., Ho C. C. K., Jackson A., Parker G. J. M., Rose C. J., Peale F. V., Friesenhahn M., Mitchell C. L., Watson Y., Roberts C., Hope L., Cheung S., Reslan H. B., Go M. A. T., Pacheco G. J., Wu X., Cao T. C., Ross S., Buonaccorsi G. A., Davies K., Hasan J., Thornton P., Del Puerto O., Ferrara N., Van Bruggen N., Jayson G. C., Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Clinical Cancer Research 2009 15 21 6674 6682
84. Miller J. C., Pien H. H., Sahani D., Sorensen A. G., Thrall J. H., Imaging angiogenesis: application and potential for drug development Journal of the National Cancer Institute 2005 97 3 172 187 (Pubitemid 40277367)
85. Juanyin J., Tracy K., Zhang L., Munasinghe J., Shapiro E., Koretsky A., Kelly K., Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model Clinical and Experimental Metastasis 2009 26 5 403 414
86. Yokota T., Oritani K., Butz S., Kokame K., Kincade P. W., Miyata T., Vestweber D., Kanakura Y., The endothelial antigen ESAM marks primitive hematopoietic progenitors throughout life in mice Blood 2009 113 13 2914 2923
87. Paulsson J., Sjblom T., Micke P., Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer American Journal of Pathology 2009 175 1 334 342
88. Jubb A. M., Cesario A., Ferguson M., Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases British Journal of Cancer 2011 104 12 1877 1881
89. Kakolyris S., Giatromanolaki A., Koukourakis M., Kaklamanis L., Kouroussis C., Bozionelou V., Georgoulias V., Gatter K. C., Harris A. L., Assessement of vascular maturation in lung and breast carcinomas using a novel basement membrane component, LH39 Anticancer Research 2001 21 6 B 4311 4316 (Pubitemid 34240961)
90. Toi M., Atiqur Rahman M., Bando H., Chow L. W. C., Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment The Lancet Oncology 2005 6 3 158 166 (Pubitemid 40309127)
91. Bertolini F., Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells Cancer and Metastasis Reviews 2008 27 1 95 101
92. Goon P. K. Y., Lip G. Y. H., Stonelake P. S., Blann A. D., Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham prognostic index Neoplasia 2009 11 8 771 779
93. Calleri A., Bono A., Bagnardi V., Quarna J., Mancuso P., Rabascio C., Dellapasqua S., Campagnoli E., Shaked Y., Goldhirsch A., Colleoni M., Bertolini F., Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab Clinical Cancer Research 2009 15 24 7652 7657